Q-omics provides the consensus-scored LIN52 profile across patient tissues and cancer cell-line models. LIN52 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LIN52 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LIN52 RNA expression shows 21,744 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where LIN52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIN52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIN52 survival associations across molecular data types. LIN52 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIN52 RNA expression–survival associations across cancer types. High LIN52 expression shows unfavorable associations in ACC, LIHC and MESO, but favorable associations in KIRC, BRCA and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LIN52 RNA expression.
This table summarizes LIN52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LIN52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIN52 shows lower tumor expression in KIRC, KICH, KIRP and THCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher LIN52 RNA expression in tumor versus normal tissue (log2 FC = +1.014, t-test p < 0.001).
This table shows molecular features associated with LIN52 in patient tissues and cancer cell lines. In patient samples, LIN52 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LIN52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUSC.
